Larvol Delta - A-LongTerm-Safety-Followup-Registry-for-Patients-Who-Received-Treatment-With-Prademagene-Zamikeracel-for-Recessive-Dystrophic-Epidermolysis-Bullosa-RDEB-in-the-PostMarketing-Setting

Zevaskyn (prademagene zamikeracel) - Abeona Therap

EB101 - Exom BioPharma

http://clinicaltrials.gov/ct2/show/NCT07700966

Jul 15, 2026

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next